Catechin-Amino Acid Complex for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gastroenteric compositions for oral administration of monomeric (+)-catechin lack stability and bioavailability, limiting their effectiveness in treating degenerative diseases and requiring high doses with potential side effects.
Innovation Solution
A gastroenteric composition with a molar equivalence ratio of (+)-monomeric catechin to basic amino acids between 1:1.5 and 1:2.5, forming a complex that enhances solubility and bioavailability by facilitating intestinal absorption, thereby increasing plasma concentrations and maintaining therapeutic levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If monomeric (+)-catechin is administered orally in pure form, then the formulation is simple, but the bioavailability is low and stability is poor
Solution Approach 1:
The patent applies composite materials by forming a complex between monomeric (+)-catechin and basic amino acids (lysine or arginine) in specific molar ratios (1:1.5 to 1:2.5). This composite structure combines the therapeutic properties of catechin with the absorption-enhancing characteristics of amino acids, resulting in improved oral bioavailability and stability while maintaining formulation simplicity
Solution Approach 2:
The patent utilizes parameter changes by optimizing the molar equivalence ratio between catechin and basic amino acids to a specific range (1:1.5 to 1:2.5). This parameter optimization transforms the poor bioavailability of pure catechin into high bioavailability of the complex, while the physiological pH environment (pH 6-8) further enhances the stability and absorption of the complex formulation
2Reliability
If high doses of monomeric (+)-catechin are administered to achieve therapeutic levels, then the therapeutic effect is sufficient, but side effects increase and treatment costs increase
Solution Approach 1:
The patent applies parameter changes by optimizing the molar ratio of catechin to basic amino acids (1:1.5 to 1:2.5) and utilizing the physiological pH environment (pH 6-8) to enhance absorption efficiency. This allows achieving therapeutic plasma concentrations with lower administered doses, thereby reducing side effects and treatment costs while maintaining reliable therapeutic effects
3Ease of operation
If monomeric (+)-catechin is administered orally, then the administration route is convenient, but the compound is not well assimilated by the body
Solution Approach 1:
The patent applies the intermediary principle by using basic amino acids (lysine or arginine) as mediators to facilitate the absorption of monomeric (+)-catechin. These amino acids act as carriers that enhance intestinal wall permeability and improve assimilation efficiency, while maintaining the convenient oral administration route. The complex formulation enables the catechin to cross the intestinal barrier more effectively than in its pure form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex formulation achieves high oral bioavailability, reducing treatment costs and side effects by allowing lower doses, with a significant increase in plasma concentrations and prolonged therapeutic action.
Implementation Method 1
said compound is in complex form and has a molar equivalence ratio of said monomeric (+)-catechin relative to said at least one basic amino acid of between 1:1.5 and 1:2.5
Data Source
Figure 1a
Figure 1b
Figure 2a
AI summary
The invention relates to a gastro-enteric composition comprising a compound of monomeric (+)- catechin and at least one basic amino acid or at least one derivative of a basic amino acid, said compound being in the form of a complex having a molar equivalence ratio of said monomeric (+)- catechin to the at least one basic amino acid or its derivative of between 1: 1 and 1: 2.5, preferably between 1: 1 and 1: 2.